Table 1.
Summary of the clinical parameters and pharmacotherapies used for correlation analyses. Data are given as mean values with range unless stated otherwise.
| Pre-Pandemic (n = 100) |
Pandemic (n = 100) |
|
|---|---|---|
| Clinical Parameters | ||
| Smoking former/ongoing (n) | 31/11 | 44/5 |
| BMI | 26.75 (range: 17.04–42.67) | 27.06 (range: 17.07–45.73) |
| Blood group 0 (n) | 38 | 38 |
| Blood group A (n) | 37 | 37 |
| Blood group B (n) | 11 | 11 |
| Blood group AB | 4 | 4 |
| Rh+ (n) | 78 | 78 |
| Rh− (n) | 12 | 12 |
| Hemoglobin | 130.7 (range: 93–169) | 130.2 (range 102–169) |
| Erythrocyte sedimentation rate (ESR) [mm/h] | 20 (range: 2–108) | 18.3 (range: 1–106) |
| WBC | 6.5 (range: 2.5–14.6) | 8.5 (range: 2.8–155) |
| Platelet count | 253.3 (range: 1.9–500) | 250.0 (range: 102–508) |
| Neutrophil count | 4.6 (range: 0.02–10.8) | 5.3 (range: 1.6–43) |
| Lymphocyte count | 1.3 (range: 0.4–3.8) | 1.5 (range: 0.3–4.5) |
| Plasma creatinine | 73.9 (range: 31–165) | 77.4 (range: 40–527) |
| Plasma albumin | - | 39.1 (range: 28–50) |
| C-reactive protein (CRP) [mg/L] | 6.8 (range: 2.5–172) | 6.1 (range: 2.5–166) |
| Complement protein 3 (C3) [g/L] | 1.06 (range: 0.4–1.8) | 0.98 (range: 0.5–2) |
| Complement protein 4 (C4) [g/L] | 0.19 (range: 0.02–0.55) | 0.18 (range: 0.02–0.53) |
| Malar rash (ACR1) (n) | 33 | 35 |
| Discoid rash (ACR2) (n) | 11 | 12 |
| Photosensitivity (ACR3) (n) | 48 | 48 |
| Oral ulcers (ACR4) (n) | 14 | 14 |
| Arthritis (ACR5) (n) | 78 | 80 |
| Serositis (ACR6) (n) | 29 | 29 |
| Renal disorder (ACR7) (n) | 34 | 34 |
| Neurologic disorder (ACR8) (n) | 10 | 10 |
| Hematologic disorder (ACR9) (n) | 58 | 62 |
| Immunological disorder (ACR10) (n) | 57 | 61 |
| Antinuclear antibody (ACR11) (n) | 99 | 99 |
| mSLEDAI (score) | 1.34 (range: 0–13) | 0.82 (range: 0–22) |
| Anti-SSA/Ro52 Antibody levels [U/mL] | 50.6 (range: 2–246) | 47.2 (range: 0–254) |
| Anti-SSA/Ro60 Antibody levels [U/mL] | 35.6 (range: 0–149) | 34.2 (range: 0–178) |
| Anti-SSB/La Antibody levels [U/mL] | 21.8 (range: 0–151) | 19.5 (range: 0–150) |
| Anti-Sm/RNP Antibody levels [U/mL] | 6.5 (range: 0–218) | 2.8 (range: 0–75) |
| Anti-U1RNP Antibody levels [U/mL] | 34.5 (range: 0–300) | 27.6 (range: 0–327) |
| Anti-dsDNA Antibody levels [U/mL] | 95.95 (range: 2–900) | 101.28 (range: 0–1081) |
| Pharmacotherapy | ||
| Immunosuppressives | ||
| Prednisolone dose [mg/day] | 4.5 (range:0–30) | 3.5 (range: 0–15) |
| Azathioprine (n) | 8 | 8 |
| Methotrexate (n) | 8 | 9 |
| Mycophenolate mofetil (n) | 21 | 23 |
| Other | ||
| Hydroxychloroquine (n) | 77 | 73 |